Progress in Diabetes Care: Islet Cell Transplants Without Immunosuppression

Sana Biotechnology has released initial results from a first-in-human study evaluating its hypoimmune (HIP) technology in type 1 diabetes treatment. The study, conducted in collaboration with Uppsala University Hospital, involved the transplantation of HIP-engineered pancreatic islet cells into a patient with type 1 diabetes. The approach aims to restore insulin production without the use of […]